PYC Therapeutics Advances RP11 Drug Trials
Prota Therapeutics' CEO Mimi Tang Honoured at BioMelbourne Network's Women in Leadership Awards 2024
Alterity Therapeutics Aims for ASX Listing Boost
Exopharm Ltd. Acquires Tryp Therapeutics
Alterity Therapeutics' Breakthrough in Rare Disease Treatment
New Safety Risk for MorphoSys Drug Could Complicate Novartis Deal - STAT
A new safety risk related to Morphosys's (NASDAQ:MOR) pelabresib, an experimental treatment for myelofibrosis, could complicate the company's planned $3B sale to Novartis (NYSE:NVS).